pubmed.ncbi.nlm.nih.gov

Clinical, Molecular, and Computational Analysis Showed a Novel Homozygous Mutation Among the Substrate-Binding Site of ARSA Protein in Consanguineous Family with Late-Infantile MLD - PubMed

Case Reports

Clinical, Molecular, and Computational Analysis Showed a Novel Homozygous Mutation Among the Substrate-Binding Site of ARSA Protein in Consanguineous Family with Late-Infantile MLD

Abir Ben Issa et al. J Mol Neurosci. 2018 Sep.

Abstract

Metachromatic leukodystrophy (MLD) is a neurodegenerative disorder characterized by progressive demyelination resulting from impaired degradation and thus the accumulation of cerebroside-3-sulfate (sulfatide). It is caused by the deficiency of arylsulfatase A (ARSA) enzyme which is encoded by the ARSA gene. The present study reports the clinical, molecular, and bioinformatic investigation of three patients belonging to a consanguineous family with late-infantile MLD disorder. The results revealed a novel homozygous missense mutation c.699C>A (p.His231Gln) in exon 4 of ARSA gene in the three patients inherited from their heterozygous parents. Interestingly, this novel mutation is the second mutation identified in the substrate-binding site of ARSA protein and it was classified as damaging and deleterious by several bioinformatics tools. The c.699C>A (p.His231Gln) leads to changes in the pre-mRNA secondary structure and in the ARSA protein 3D structure with a significant root mean square deviation value which could probably affect its stability and function.

Keywords: ARSA gene; Arylsulfatase A; Late-infantile MLD.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Hum Mutat. 1999 Nov;14(5):447 - PubMed
    1. Hum Mol Genet. 2001 Mar 15;10(6):591-7 - PubMed
    1. Genome Res. 2001 May;11(5):863-74 - PubMed
    1. Biochem J. 2002 Oct 15;367(Pt 2):499-504 - PubMed
    1. Biotechniques. 1992 Oct;13(4):522-4 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources